Literature DB >> 26685103

Robust exchangeability designs for early phase clinical trials with multiple strata.

Beat Neuenschwander1, Simon Wandel1, Satrajit Roychoudhury2, Stuart Bailey3.   

Abstract

Clinical trials with multiple strata are increasingly used in drug development. They may sometimes be the only option to study a new treatment, for example in small populations and rare diseases. In early phase trials, where data are often sparse, good statistical inference and subsequent decision-making can be challenging. Inferences from simple pooling or stratification are known to be inferior to hierarchical modeling methods, which build on exchangeable strata parameters and allow borrowing information across strata. However, the standard exchangeability (EX) assumption bears the risk of too much shrinkage and excessive borrowing for extreme strata. We propose the exchangeability-nonexchangeability (EXNEX) approach as a robust mixture extension of the standard EX approach. It allows each stratum-specific parameter to be exchangeable with other similar strata parameters or nonexchangeable with any of them. While EXNEX computations can be performed easily with standard Bayesian software, model specifications and prior distributions are more demanding and require a good understanding of the context. Two case studies from phases I and II (with three and four strata) show promising results for EXNEX. Data scenarios reveal tempered degrees of borrowing for extreme strata, and frequentist operating characteristics perform well for estimation (bias, mean-squared error) and testing (less type-I error inflation).
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian; between-strata heterogeneity; exchangeability-nonexchangeability; hierarchical model; pooling; shrinkage; stratification

Mesh:

Year:  2015        PMID: 26685103     DOI: 10.1002/pst.1730

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  17 in total

1.  Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.

Authors:  Nan Chen; J Jack Lee
Journal:  Biom J       Date:  2018-12-03       Impact factor: 2.207

2.  An efficient basket trial design.

Authors:  Kristen M Cunanan; Alexia Iasonos; Ronglai Shen; Colin B Begg; Mithat Gönen
Journal:  Stat Med       Date:  2017-01-18       Impact factor: 2.373

3.  Variance prior specification for a basket trial design using Bayesian hierarchical modeling.

Authors:  Kristen M Cunanan; Alexia Iasonos; Ronglai Shen; Mithat Gönen
Journal:  Clin Trials       Date:  2018-12-07       Impact factor: 2.486

Review 4.  Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases.

Authors:  Yimei Li; Rima Izem
Journal:  Ann Transl Med       Date:  2022-09

Review 5.  Challenges, opportunities, and innovative statistical designs for precision oncology trials.

Authors:  Jun Yin; Shihao Shen; Qian Shi
Journal:  Ann Transl Med       Date:  2022-09

Review 6.  Innovations for phase I dose-finding designs in pediatric oncology clinical trials.

Authors:  Adelaide Doussau; Birgit Geoerger; Irene Jiménez; Xavier Paoletti
Journal:  Contemp Clin Trials       Date:  2016-01-26       Impact factor: 2.226

7.  Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.

Authors:  P S Boonstra; T M Braun; J M G Taylor; K M Kidwell; E L Bellile; S Daignault; L Zhao; K A Griffith; T S Lawrence; G P Kalemkerian; M J Schipper
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

8.  Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.

Authors:  Haiyan Zheng; James M S Wason
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

Review 9.  Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.

Authors:  Chengxing Cindy Lu; Xiaoyun Nicole Li; Kristine Broglio; Paul Bycott; Qi Jiang; Xiaoming Li; Anna McGlothlin; Hong Tian; Jingjing Ye
Journal:  Ther Innov Regul Sci       Date:  2021-06-23       Impact factor: 1.778

10.  Master protocol trials in oncology: Review and new trial designs.

Authors:  Akihiro Hirakawa; Junichi Asano; Hiroyuki Sato; Satoshi Teramukai
Journal:  Contemp Clin Trials Commun       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.